GGrantIndex
← Search

PRECLINICAL ADVANCEMENT OF NOVEL MECHANISM-OF-ACTION THERAPEUTICS TO COMBAT TYPE 2 DIABETES IN US VETERANS

$4,192,268FY2019Department of the ArmyDOD

Ridgeline Therapeutics Llc

Investigators

View source on USAspending →
PRECLINICAL ADVANCEMENT OF NOVEL MECHANISM-OF-ACTION THERAPEUTICS TO COMBAT TYPE 2 DIABETES IN US VETERANS · GrantIndex